378 related articles for article (PubMed ID: 27476551)
1. Pharmacokinetics, pharmacodynamics and clinical efficacy of ospemifene for the treatment of dyspareunia and genitourinary syndrome of menopause.
Bondi C; Ferrero S; Scala C; Tafi E; Racca A; Venturini PL; Leone Roberti Maggiore U
Expert Opin Drug Metab Toxicol; 2016 Oct; 12(10):1233-46. PubMed ID: 27476551
[TBL] [Abstract][Full Text] [Related]
2. Safety and efficacy of ospemifene for the treatment of dyspareunia associated with vulvar and vaginal atrophy due to menopause.
Wurz GT; Kao CJ; DeGregorio MW
Clin Interv Aging; 2014; 9():1939-50. PubMed ID: 25419123
[TBL] [Abstract][Full Text] [Related]
3. Ospemifene for the treatment of postmenopausal vulvar and vaginal atrophy: recommendations for clinical use.
Pinkerton JV; Kagan R
Expert Opin Pharmacother; 2015; 16(17):2703-14. PubMed ID: 26634778
[TBL] [Abstract][Full Text] [Related]
4. A cost-effectiveness analysis of vaginal carbon dioxide laser therapy compared with standard medical therapies for genitourinary syndrome of menopause-associated dyspareunia.
Wallace SL; St Martin B; Lee K; Sokol ER
Am J Obstet Gynecol; 2020 Dec; 223(6):890.e1-890.e12. PubMed ID: 32562659
[TBL] [Abstract][Full Text] [Related]
5. Ospemifene: a first-in-class, non-hormonal selective estrogen receptor modulator approved for the treatment of dyspareunia associated with vulvar and vaginal atrophy.
DeGregorio MW; Zerbe RL; Wurz GT
Steroids; 2014 Nov; 90():82-93. PubMed ID: 25087944
[TBL] [Abstract][Full Text] [Related]
6. Ospemifene, a non-oestrogen selective oestrogen receptor modulator for the treatment of vaginal dryness associated with postmenopausal vulvar and vaginal atrophy: a randomised, placebo-controlled, phase III trial.
Portman D; Palacios S; Nappi RE; Mueck AO
Maturitas; 2014 Jun; 78(2):91-8. PubMed ID: 24679891
[TBL] [Abstract][Full Text] [Related]
7. Ospemifene for the treatment of menopausal vaginal dryness, a symptom of the genitourinary syndrome of menopause.
Archer DF; Simon JA; Portman DJ; Goldstein SR; Goldstein I
Expert Rev Endocrinol Metab; 2019 Sep; 14(5):301-314. PubMed ID: 31526199
[No Abstract] [Full Text] [Related]
8. Long-term safety of ospemifene (52-week extension) in the treatment of vulvar and vaginal atrophy in hysterectomized postmenopausal women.
Simon J; Portman D; Mabey RG;
Maturitas; 2014 Mar; 77(3):274-81. PubMed ID: 24411556
[TBL] [Abstract][Full Text] [Related]
9. Profile of ospemifene in the breast.
Berga SL
Reprod Sci; 2013 Oct; 20(10):1130-6. PubMed ID: 23945733
[TBL] [Abstract][Full Text] [Related]
10. Ospemifene for the treatment of dyspareunia in postmenopausal women.
Paton DM
Drugs Today (Barc); 2014 May; 50(5):357-64. PubMed ID: 24918836
[TBL] [Abstract][Full Text] [Related]
11. Ospemifene: first global approval.
Elkinson S; Yang LP
Drugs; 2013 May; 73(6):605-12. PubMed ID: 23605694
[TBL] [Abstract][Full Text] [Related]
12. Ospemifene for the treatment of vulvovaginal atrophy and dyspareunia in postmenopausal women.
McLendon AN; Clinard VB; Woodis CB
Pharmacotherapy; 2014 Oct; 34(10):1050-60. PubMed ID: 25052122
[TBL] [Abstract][Full Text] [Related]
13. Treatment of the genitourinary syndrome of menopause.
Palacios S; Mejía A; Neyro JL
Climacteric; 2015; 18 Suppl 1():23-9. PubMed ID: 26366797
[TBL] [Abstract][Full Text] [Related]
14. The efficacy and safety of ospemifene in treating dyspareunia associated with postmenopausal vulvar and vaginal atrophy: a systematic review and meta-analysis.
Cui Y; Zong H; Yan H; Li N; Zhang Y
J Sex Med; 2014 Feb; 11(2):487-97. PubMed ID: 24251418
[TBL] [Abstract][Full Text] [Related]
15. Ospemifene in the treatment of vulvovaginal atrophy.
Barnes KN; Pearce EF; Yancey AM; Forinash AB
Ann Pharmacother; 2014 Jun; 48(6):752-7. PubMed ID: 24615631
[TBL] [Abstract][Full Text] [Related]
16. Ospemifene, a novel selective estrogen receptor modulator for treating dyspareunia associated with postmenopausal vulvar and vaginal atrophy.
Portman DJ; Bachmann GA; Simon JA;
Menopause; 2013 Jun; 20(6):623-30. PubMed ID: 23361170
[TBL] [Abstract][Full Text] [Related]
17. Ospemifene: a novel selective estrogen receptor modulator for treatment of dyspareunia.
Eder SE
Womens Health (Lond); 2014 Sep; 10(5):499-503. PubMed ID: 25335541
[TBL] [Abstract][Full Text] [Related]
18. Overall Safety of Ospemifene in Postmenopausal Women from Placebo-Controlled Phase 2 and 3 Trials.
Simon JA; Altomare C; Cort S; Jiang W; Pinkerton JV
J Womens Health (Larchmt); 2018 Jan; 27(1):14-23. PubMed ID: 29064335
[TBL] [Abstract][Full Text] [Related]
19. Effects of ospemifene on bone parameters including clinical biomarkers in postmenopausal women.
Constantine GD; Kagan R; Miller PD
Menopause; 2016 Jun; 23(6):638-44. PubMed ID: 27045700
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of ospemifene in postmenopausal women with moderate-to-severe vaginal dryness: a phase 3, randomized, double-blind, placebo-controlled, multicenter trial.
Archer DF; Goldstein SR; Simon JA; Waldbaum AS; Sussman SA; Altomare C; Zhu J; Yoshida Y; Schaffer S; Soulban G
Menopause; 2019 Jan; 26(6):611-621. PubMed ID: 30694917
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]